Amunix.com

Amunix. Amunix is an immuno-oncology company leveraging Pro-XTEN technology platform to discover and develop transformative therapies for patients...

Never miss Amunix.com updates: Start reading the news feed of Amunix right away! Unfortunately, we cannot detect RSS feed on this website, but you may observe related news or Amunix.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Amunix

Subscribe to related news

Harold E. “Barry” Selick, Ph.D. and Walter H. Moos, Ph.D. Join Amunix Board of Directors
via sauditopbusiness

MOUNTAIN VIEW, CA—(Marketwired – March 03, 2016) – Amunix is pleased to announce the appointment Harold E. “Barry” Selick and Walter H. Moos to the company's board of directors.Â “Barry and Walter are strong additions to our company; their breadth of...
Bay Area's Amunix, Inc. Strikes $70 Million+ Deal With
via biospace

Amunix Announces Exclusive Agreements With Naia to Develop GLP-1 and GLP-2 XTEN Products MOUNTAIN VIEW, CA--(Marketwired - Jan 5, 2015) - Amunix Operating Inc. (Amunix), a leader in the field of protein half-life extension, today announced a research...
Volatile Versartis May Have Significant Upside
via seekingalpha

By C.R. Jackson: Versartis, Inc., (NASDAQ:VSAR) is a $540M market cap biopharmaceutical company that is developing therapeutic proteins to treat metabolic diseases and endocrine disorders. The company's most advanced product candidate is VRS-317, a...
Naia Rare Diseases, Inc. Appoints Professor Palle Bekker Jeppesen to Its Scientific Advisory Board
via kuwaitfinancialexpress

RICHMOND, CA—(Marketwired – January 26, 2016) – Naia Limited, an international drug development company today announced that its subsidiary, Naia Rare Diseases, has appointed Professor Palle Bekker Jeppesen, MD, Head of Research at the Department of...
EuroPeptides 2014
via eventogo

Amunix.com popular pages

Nov 15 2009 - Amunix

Press Releases XTEN DATA FROM AMUNIX AND VERSARTIS FEATURED IN NATURE BIOTECHNOLOGY AS A NOVEL PLATFORM FOR INCREASING SERUM HALF-LIFE OF PROTEIN THERAPEUTICS Redwood City and Mountain View, CA – Nov...

Jan 07 2014 - Amunix

AMUNIX ANNOUNCES EXPANSION TO LICENSING AGREEMENT WITH JANSSEN FOR ITS PROPRIETARY XTEN TECHNOLOGY Mountain View, CA – January 7, 2014 – Amunix Operating Inc. (Amunix) announced today that Janssen Bio...